A B S T R A C T Recent studies of individuals with high molecular weight (HMW) 
INTRODUCTION
When normal human plasma comes into contact with negatively charged surfaces such as glass, several plasma reactions, including blood coagulation, fibrinolysis, and kinin generation, may take place. Studies of Hageman trait plasma have shown the central role of Hageman factor (Factor XII) as a common trigger of these reactions (1) (2) (3) . A further elucidation of the interrelationships among various surface-mediated plasma reactions has come about from the recent discovery of Fletcher trait (4) and Fitzgerald trait (5, 6) . Both conditions were initially described as blood-clotting abnormalities; the plasmas of affected individuals were said to be deficient in Fletcher factor and Fitzgerald factor, respectively. Subsequently, both conditions were also associated with abnormal in vitro fibrinolysis and kinin generation. Fletcher factor is a plasma prekallikrein (7) (8) (9) . An agent functionally deficient in Fitzgerald trait and other plasmas with the same clotting defect was recently identified as high molecular weight (HMW)'-kininogen (10) (11) (12) (13) (14) . Thus, these studies established that plasma prekallikrein and HMW-kininogen, proteins of the plasma kinin-forming system, also participate in blood coagulation in vitro.
The site and mode of action of HMW-kininogen in clotting is not fully understood, but this agent appears to participate early in the intrinsic pathway of thrombin formation (12) . The present paper describes the purification of HMW-kininogen and its role in blood coagulation.
Mich.
HMW-kininogen was prepared from normal human plasma by a modification of published methods (15, 16) . During purification, Fitzgerald factor activity was identified by a clotpromoting assay (12), 1 U being arbitrarily defined as that amount present in 1 ml of normal pooled plasma. The sample was diluted more than 20-fold in barbital-saline buffer. The kininogen content of our preparations was also monitored as described previously (17) .
Step 1. Batch absorption and elution from quaternary aminoethyl-(QAE) Sephadex. 2 U of blood was collected into polystyrene bottles containing 0.02 vol of 0.5 M sodium citrate (pH 5.0) and 50 mM benzamidine HCI (Eastman Kodak Co., Rochester, N.Y.). To -500 ml plasma was added 0.01 vol of 0.01 M EDTA and 5 mg of hexadimethrine bromide (Polybrene, Aldrich Chemical Co., Inc., Milwaukee, Wis.) per ml. The plasma was adsorbed with 0.02 vol of alumina Cy-gel (Calbiochem, San Diego, Calif.) for 10 min at room temp. After centrifugation, the supematant plasma was dialyzed overnight against two changes of 10 vol of 0.025 M Tris-HCl buffer (pH 7.5) containing 0.1 M NaCl, 0.1 mM EDTA, 1 mM benzamidine, 0.05 mg Polybrene/ml, and 0.02% sodium azide. The dialyzed plasma was mixed for 45 min at room temp with -800 ml settled volume of QAE-Sephadex A-50 (Pharmacia Fine Chemicals, Div. of Pharmacia Inc., Piscataway, N.J.) equilibrated with the buffer described. The mixture was allowed to settle, the supematant plasma was discarded, and the settled gel was mixed with fresh buffer and poured into a plastic column (5-cm diameter), and the column was washed with the same buffer for 2 days. At this step, HMWkininogen, attached to the gel, was completely separated from plasma thromboplastin antecedent (PTA, Factor XI) and plasma prekallikrein (Fletcher factor). The washed QAESephadex A-50 gel was transferred to a beaker and was eluted four times with 300 ml each of 0.025 M Tris-Cl buffer (pH 7.5) containing 0.5 M NaCl and EDTA-benzamidine-Polybrene-sodium azide, and the eluates with Fitzgerald factor clotting activity were combined. After addition of benzamidine to a final concentration of 2 mM, material was precipitated by the addition of solid ammonium sulfate to 60% saturation.
Step 2. QAE-Sephadex column. The precipitate was dissolved in 0.025 M Tris-Cl buffer (pH 7.5) containing 0.1 M NaCl-EDTA-benzamidine-Polybrene-sodium azide, dialyzed against the same buffer, and applied to a column of QAESephadex A-50 (2.5 x 38 cm), previously equilibrated with the same buffer. Protein was eluted with a linear salt gradient of 500 ml each of the equilibrating buffer and 0.025 M Tris-Cl buffer (pH 7.5) containing 0.5 M NaCl-EDTAbenzamidine-Polybrene-sodiuim azide. HMW-kininogen was eluted between 0.3 and 0.4 M NaCl, separated from Hageman factor (HF, Factor XII) activity which was eluted before a concentration of 0.25 M NaCl was reached. The HMW-kininogen-rich fractions were pooled and, after the addition of benzamidine to 2 mM, solid ammonium sulfate was added to 60% saturation. The precipitate was frozen at -20°C, and the same procedures (steps 1 and 2) were repeated with an additional 4 U of blood.
Step 3. Gel filtration on Ultragel and Sephadex G-200. The precipitate from 6 U of blood was dissolved in 0.1 M Tris-Cl buffer (pH 7.5) containing 0.2 M NaCl-benzamidinePolybrene-sodium azide and dialyzed against the same buffer. The dialyzed solution (23 ml) was divided into two parts, and each part was filtered through a 2.6 x 89-cm silicone-coated glass column of Ultragel AcA 34 (LKBProdukter AB, Bromma, Sweden) that had been preswollen in the same buffer; approximately 11-ml fractions were collected at a flow rate of 10 ml/h. The peak tubes were pooled and, after benzamidine was added to 2 mM final concentration, solid ammonium sulfate was added to 60% saturation. The resultant precipitate from two runs (-7 ml) was dissolved and dialyzed against the above buffer. Diisopropylfluorophosphate (Sigma Chemical Co., St. Louis, Mo.) in 1,2-dipropyl alcohol was added to the dialyzed soltution to a final concentration of 0.02 M, and the mixture was incubated overnight at room temp (16) . The solution was then filtered through a2.5 x 87-cm column of Sephadex G-200 equilibrated with the buffer described. The HMW-kininogen-rich fractions were pooled, concentrated by ammonium sulfate precipitation, dissolved, and dialyzed against 0.05 M sodium acetate buffer (pH 6.2) containing 0.125 M NaCl and 1 mM benzamidine. All procedures Up to this point were performed at room temperature. Ste) 4. Carboxymethyl-(CM-)Sephadex coltmn. The dialyzed solution was applied to a 2.5 x 14-cm siliconecoated glass column of CM-Sephadex C-50 equilibrated with the same btuffer. Protein was then eltuted with a linear salt gradient of 250 ml each of the equilibrating buffer and the same buffer with 0.7 M NaCl (Fig. 1 ). 6-ml fractions were collected, and HMW-kininogen was eluted at a concentration of NaCl between 0.3 and 0.4 M. Fitzgerald factor clotting activity showed only a single peak and was not separated from kininogen in these fractionation procedures. On the CM-Sephadex C-50 column, peaks of protein, kininogen, Fitzgerald factor clotting activity, and the ability to repair impaired fibrinolysis all eluted at the same place. Tubes containing the peak activities were pooled, dialyzed against barbital-saline btuffer (pH 7.4), and frozen at -700C.
The yield was -15%, the preparations' specific activity was 17 U/mg protein in a clot-promoting assay, and it released _1% of the weight of protein as bradykinin when treated with trypsin or plasma kallikrein. Upon analytical polyacrylamide gel electrophoresis (18) , two protein bands were stained by Coomassie Blue, both of which had Fitzgerald factor clotting activity as tested upon segments of replicate gels. Upon sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (19) , this preparation revealed a sharp single band with an approximate mol wt of 120,000. Protein standards employed were: bovine pancreatic chymotrypsinogen A, 25,000 (Pharmacia Fine Chemicals); pepsin, 35,000 (Worthington Biochemical Corp., Freehold, N.J.); human serum albumin, 68,000; type I bovine thyroglobulin, 160,000; Escherichia coli f3-galactosidase, 135 ,000 (all from Sigma Chemical Co.); and human transferrin, 88,000 (BehringWerke A.G., Marburg, Germany).
Purified clotting factors, antibodies against clotting factors and procoagulant assays of HF, PTA, and plasma prekallikrein were prepared or performed as described earlier (4, (20) (21) (22) . One unit of the procoagulant activity was arbitrarily defined as that amount present in 1 ml of a standard pooled plasma. Two preparations of PTA were used; partially purified (52 U/mg protein) and highly purified (200 U/mg protein). The major contaminant of the former preparation was IgG, but both preparations, tested at 4 U/mI were free of any detectable activity attributable to HF, prekallikrein, HMWkininogen, plasminogen, and plasmin. The highly purified PTA had an apparent mol wt of 160,000 on SDS gel electrophoresis. A preparation of HF (59 U/mg protein) was free of detectable activity attributable to other clotting factors (<0.01 U/ml) when tested at 8 U/ml. It The presence of plasma prekallikrein in the preparations of HF, PTA, and HMW-kininogen was also tested by a radioimmunoassay that can quantitatively measure as little as 0.003 U/ml (23) . Prekallikrein antigen was absent by this assay in the plasma of a patient with Fletcher trait, and there was a good correlation (coefficient = 0.71) between radioimmunoassays and clotting assays of 40 normal plasmas.
Antibodies against HF, PTA, and HMW-kininogen were crude IgG fraction of rabbit antiserum. They were functionally and immunologically monospecific. IgG fraction from normal rabbit serum was used as a control.
Kaolin-induced fibrinolysis (8), kinin-like activity (8) , and the effect of incubating plasma with kaolin at 0°C (12) 586 H. Saito upon the Thrombotest time were studied as reported previously.
The effect of trypsin and plasma kallikrein upon HMWkininogen was studied by incubating 1 ml HMW-kininogen (2 U/ml, 0.115 mg protein/ml) with 0.08 ml of either bovine trypsin (0.1 mg/ml, twice-crystallized, dialyzed salt-free and lyophilized, Worthington Biochemical Corp.) or human plasma kallikrein (0.17 mg/ml) or barbital-saline buffer in a 12 x 75-mm polystyrene tube at 37°C. At various intervals, 0.16-ml aliquots were transferred to 10 x 75-mm polystyrene tubes containing 0.04 ml soybean trypsin inhibitor (0.1 mg/ml, Worthington Biochemical Corp.) and 0.02 ml 0.01 M o-phenanthroline (Fisher Scientific Co., Inc., Pittsburgh, Pa.). 0.07-ml aliquots of these mixtures were subjected to analytical disc-gel electrophoresis, 0.01-0.03 ml were used for assay of kinin, and the rest was used for HMW-kininogen clotting assays after appropriate dilution in barbital-saline buffer. HMW-kininogen incubated with buffer was used as a control.
The activation of PTA in a purified system was studied by incubating 0.075 ml PTA (0.023-0.2 U/ml) with 0.025 ml HF (0.01-1.8 U/ml), 0.025 ml prekallikrein (0.1 U/ml), 0.025 ml HMW-kininogen (0.0025-1 U/ml), and 0.075 ml ellagic acid (synthesized by Dr. J. Crum, Case Western Reserve University or obtained from K & K Laboratories, Inc., Plainview, N.Y., 0.1-0.001 mM in barbital-saline buffer) in a 10 x 75-mm polystyrene tube at 37°C. In some experiments, 0.02 ml kaolin (2 mg/ml) was used instead of ellagic acid. At intervals, 0.05-ml aliquots were transferred to prewarmed 10 x 75-mm polystyrene tubes containing 0.1 ml Centrolex 0 (Central Soya Co., Inc., Fort Wayne, Ind.) and 0.1 ml PTA-deficient plasma. 0.1 ml of 0.025 M CaCi2 was immediately added and the clotting time was measured by tilting a tube at a constant rhythm (30 times/min), using a metronome as a pacer. The results were expressed as the clotting time and as the percentage of the activated PTA activity relative to that of the sample with the greatest activity. All purified clotting factors were diluted in 0.1% bovine serum albumin (BSA, crystallized, Pentex, Miles Laboratories, Kankakee, Ill.) and prewarmed at 37°C for 2 min before they were mixed together in the above system. The BSA used in these experiments was free of any known clotting factor activity and inhibitors of activated PTA. Other modifications used are described in the legends to tables and figures. The activation of PTA by HF-fragments was studied in the same way except HF-fragments (27 ,ug/ml) were used instead of HF.
The possibility that HF may be fragmented in a mixture of HF, PTA, HMW-kininogen, and ellagic acid was studied as follows. 0.04 ml 1251-HF (0.4 U/ml, _25,000 cpm), prepared as described (24), was incubated with 0.01 ml partially purified PTA (0.2 U/ml) or highly purified PTA (0.5 U/ml), 0.005 ml HMW-kininogen (1 U/ml) and 0.02 ml ellagic acid (0.1 mM) or barbital-saline buffer in a 10 x 95-mm polystyrene tube at 37°C. At 0, 10, 20, and 30 min, 0.1 ml 4% SDS and 1% /8-mercaptoethanol was added to the tube, and the tube was boiled for 3 min. The mixture was subjected to SDS-gel electrophoresis. The gel was cut into 2-mm segments, and the radioactivity of each segment was counted on a gamma counter (Nuclear-Chicago, model 1085, Searle Analytic Inc., Des Plaines, Ill.).
RESULTS
The effect of HMW-kininogen upon the impaired surface-mediated plasma reactions ofvarious plasmas. Plasmas from individuals with Hageman trait, Fletcher trait, and Fitzgerald trait are known to demonstrate impaired surface-mediated reactions such as blood coagulation, fibrinolysis, kinin generation, and augmentation of Factor VII activity (1) (2) (3) (4) (5) (6) (7) (8) (9) . Addition of HMW-kininogen specifically corrected all of impaired surface-mediated plasma reactions of Fitzgerald trait plasma, but not those of Hageman trait or Fletcher trait plasma.
The effect of treatment of HMW-kininogen with plasma kallikrein or trypsin. When HMW-kininogen was incubated with trypsin, kinin activity was progressively generated with time, reaching a maximum (m 1% of HMW-kininogen on the weight basis) in 10 min. The clot-promoting activity of HMW-kininogen, as tested with Fitzgerald trait plasma, rapidly decreased during this period (Fig. 2) . After 10 min, when all kinin activity was released, only 1% of the original clotting activity remained. A mixture of equal amounts of unincubated aliquots and aliquots incubated for 30 min contained -50% of the original clot-promoting activity of unincubated aliquots, as though no inhibitor of clotting generated during incubation. Upon analytical disc gel electrophoresis, the original two bands disappeared, and a single band with faster mobility appeared as incubation proceeded. In contrast, when HMW-kininogen was incubated with plasma kallikrein, there was no loss of the clot-promoting activity even after kinin generation was apparently complete (Fig. 3) , and its capacity to Incubation time (mi)n FIGURE 2 The effect of trypsin upon HMW-kininogen. 1 ml HMW-kininogen (2 U/ml, 0.115 mg/ml) was incubated with 0.08 ml trypsin (0.1 mg/ml) in a 12 x 75-mm polystyrene tube at 370C. At timed intervals, 0.16-ml aliquots were transferred into 10 x 75-mm polystyrene tubes containing 0.04 ml soybean trypsin inhibitor (0.1 mg/ml) and 0.02 ml 0.01 M o-phenanthroline. A 0.07-ml aliquot was subjected to analytical disc gel electrophoresis, and the rest of the aliquot was used to measure kinin activity and HMW-kininogen clotting activity. The patterns of disc-gel electrophoresis at 0, 2, and 10 min are shown from left to right.
correct the fibrinolytic defect of Fitzgerald trait plasma was retained. The pattern of disc gel electrophoresis showed that the mobility of the faster-moving band slowed slightly and that two bands became closer to each other. The role of HMW-kininogen in the activation of PTA by HF and ellagic acid. When highly purified PTA was incubated with HF, plasma prekallikrein, HMW-kininogen, and ellagic acid, clot-promoting activity generated progressively as incubation proceeded (Table I) tested by a sensitive radioimmunoassay. HF at 16 U/ml, highly purified and partially purified PTA at 4 U/ml, and HMW-kininogen at 2 U/ml contained <0.003 U/ml prekallikrein. In the following experiments, partially purified PTA was used. Evidence that activated PTA activity was generated in a mixture of HF, PTA, HMW-kininogen, and ellagic acid came from the following experiments. First, when aliquots of the mixture were tested on a substrate of Christmas factor (Factor IX)-deficient plasma, there was no shortening of the clotting time. Second, antibodies against HF, PTA, and HMW-kininogen all abolished the generation of clot-promoting activity in the incubation mixture when these were added before the addition of ellagic acid (Fig. 4A) . None of the antibodies except anti-PTA, however, inactivated clot-promoting activity after HF, PTA, and HMW-kininogen were incubated with ellagic acid for 10 min (Fig. 4B) In a 10 x 75-mm polystyrene tube the following reagents were incubated at 37°C: 0.075 ml highly purified PTA (0.05 U/ml), 0.025 ml HF (0.18 U/ml), 0.025 ml prekallikrein (0.1 U/ml) or BSA, 0.025 ml HMW-kininogen (K) (0.2 U/ml) or BSA, and 0.075 ml 0.1 mM ellagic acid (EA). At intervals, 0.05-ml aliquots were tested for activated PTA as described in Methods. The results were the arithmetic sum of the triplicate determinations. Incubation time (min ) FIGURm 4 (A) The effect of antibodies against HF, PTA, and HMW-kiniogen upon the generation of clot-promoting activity. In a 10 x 75-mm polystyrene tube, 0.075 ml PTA (0.2 U/ml) was incubated at 37°C with 0.025 ml HF (0.18 U/ml), 0.025 ml HMW-kininogen (0.04 U/ml), and 0.025 ml antibodies against HF, PTA, or HMW-kininogen or normal rabbit IgG. After 5 min, 0.075 ml ellagic acid (0.1 mM) was then added to the mixture and the mixture was further incubated. At timed intervals, 0.05-ml aliquots were tested for activated PTA activity as described in Methods. (B) The effect of antibodies against HF, PTA, and HMW-kininogen upon generated clot-promoting activity. In a 10 x 75-mm polystyrene tube, 0.105 ml PTA (0.2 U/ml) was incubated at 37°C with 0.035 ml HF (0.18 U/ml), 0.035 ml HMW-kininogen (0.04 U/ml), 0.035 ml BSA, and 0.105 ml ellagic acid (0.1 mM). After 10 min, the mixture was divided into 0.06-ml aliquots and to each aliquot was added 0.012 ml of antibodies against HF, PTA, or HMW-kininogen or normal rabbit IgG. The mixtures were incubated at 37°C for 5 min, and 0.06-ml aliquots were tested for activated PTA activity as described in Methods. appreciably change the rate or degree of generation of activated PTA activity. HMW-kininogen retained its clot-promoting activity in a purified system after all kinin activity was removed by treatment with plasma kallikrein.
The way in which PTA was activated was investigated by testing the effect of varying concentration of either HF, PTA, HMW-kininogen, or ellagic acid on the evolution of activated-PTA activity. Since each protein was diluted in this experiment, the stability of the clot-promoting activity of each protein was first examined. The activities of HF, PTA, and HMWkininogen were stable at any concentration used in the following experiments as tested on the respective substrate plasmas after incubation for 30 min at 37°C.
When the concentration of PTA was varied over a ninefold range and the concentration of other reagents was kept constant, the yield of activated PTA activity varied in proportion to the concentration of PTA (Fig. 5) . After 10 min, when the generation of activated PTA activity reached a plateau, further additions of each reagent were made to the mixture. Only the addition of PTA resulted in a ftirther generation of clot-promoting activity (Fig. 6 ). When the concentration of HMW-kininogen was varied over a 16-fold range, and the concentration of other reagents was kept constant, the yield of activated PTA activity varied in proportion to the concentration of HMW-kininogen (Fig. 7) . After 20 min, when activated PTA activity reached its maximum, each reagent was added to the mixtture. Only the addition of HMWkininogen resulted in the further generation of clotpromoting activity under these conditions (Fig. 8) . When the concentration of HF was changed over an 18-fold range, and those of other reagents were kept Incubation time (min) FIGuRE 6 The effect of further addition of HF, HMWkininogen, PTA, and ellagic acid upon PTA activation. In a 12 x 75-mm polystyrene tube, 0.225 ml PTA (0.2 U/ml) was incubated at 37°C with 0.075 ml HF (1.8 U/ml), 0.075 ml HMW-kininogen (1 U/ml), 0.075 ml BSA, and 0.225 ml ellagic acid (0.1 mM). After incubation for 10 s or for 5 or 10 min, 0.05-ml aliquots were tested for activated PTA activity. At 10 min, as indicated by an arrow, the reaction mixture was divided into 0.1-ml aliquots, and to each 0.1-ml aliquot was added 0.025 ml of either (A) PTA (0.2 U/ml), (B) HF (1.8 U/ml), (C) HMW-kininogen (1 U/ml), (D) ellagic acid (0.1 mM), or (E) BSA. The mixtures were further incubated for 10 min, and 0.05-ml aliquots were tested as above.
constant, the yield of activated PTA activity varied in relation to the concentration of HF (Fig. 9) . When the generation of activated PTA activity reached its maximum under these conditions, only the addition of HF induced more clot-promoting activity (Fig. 10) .
Changing the concentration of ellagic acid from 0.1 to 0.001 mM did not significantly alter the generation of activated-PTA activity. When the concentration was lower than 0.001 mM, the yield of activated PTA was proportionately reduced. Thus, in these experiments the yield of activated PTA depended not only upon the concentration of PTA, but also FIGURE 5 The effect of varying the concentration of PTA upon PTA activation. In a 10 x 75-mm polystyrene tube, 0.075 ml PTA (0.2, 0.07, or 0.023 U/ml) was incubated at 37°C with 0.025 ml HF (1.8 U/ml), 0.025 ml HMW-kininogen (1 U/ml), 0.025 ml BSA, and 0.075 ml ellagic acid (0.1 mM). At timed intervals, 0.05-ml portions of this mixture were tested for activated PTA activity as described in Methods. 8 The effect of further addition of HF, HMWkininogen, PTA, and ellagic acid upon PTA activation. In a 12 x 75-mm polystyrene tube, 0.225 ml PTA (0.2 U/ml) was incubated at 370C with 0.075 ml HF (1.8 U/ml), 0.075 ml HMW-kininogen (0.0025 U/ml), 0.075 ml BSA, and 0.225 ml ellagic acid (0.1 mM). At 10 s and at 10 and 20 min, 0.05-ml aliquots were tested for activated PTA activity. At 20 min, as indicated by the arrow, the reaction mixture was divided into 0.1-ml aliquots and to each 0.1-ml aliquot was added 0.025 ml of either (A) HMW-kininogen (0.04 U/ml), (B) HF (1.8 U/ml), (C) PTA (0.2 U/ml), (D) ellagic acid (0.1 mM), or (E) BSA. The mixtures were incubated for an additional 10 min, and the 0.05-ml aliquots were then tested as above.
upon the concentrations of HF, HMW-kininogen, and ellagic acid.
The role of HMW-kininogen in the activation of PTA by HF-fragments. HF-fragments (approximate mol wt 30,000) are derived from HF (mol wt 80,000) by the action of proteolytic enzymes such as plasmin, kallikrein, or trypsin (25) (26) (27) . These fragments are very potent activators of prekallikrein, but only weakly clot-promoting (28) . The activation of PTA by HFfragments was studied in two different ways. First, the effect of HF-fragments upon the partial thromboplastin time (PTT) of various plasmas was studied Incubation time (min) FIGURE 9 The effect of varying the concentration of HF upon PTA activation. In a 10 x 75-mm polystyrene tube, 0.075 ml PTA (0.2 U/ml) was incubated at 370C with 0.025 ml HF (1.8, 0.18, 0.045, or 0.01 U/ml), 0.025 ml HMWkininogen (1 U/ml), 0.025 ml BSA, and 0.075 ml ellagic acid (0.1 mM). At timed intervals, 0.05-ml aliquots were tested for activated PTA activity as described in Methods. 10 The effect of further addition of HF, HMWkininogen, PTA, and ellagic acid upon PTA activation. In a 12 x 75-mm polystyrene tube, 0.225 ml PTA (0.2 U/ml) was incubated at 37°C with 0.075 ml HF (0.045 U/ml), 0.075 ml HMW-kininogen (0.2 U/ml), 0.075 ml BSA, and 0.225 ml ellagic acid (0.1 mM). At 10-s and at 10-and 20-min incubations, 0.05-ml aliquots were tested for activated PTA activity upon PTA-deficient plasma. At 20 min, as indicated by the arrow, the reaction mixture was divided into 0.1-ml aliquots, and to each 0.1 ml aliquot was added 0.025 ml of either (A) HF (0.8 U/ml), (B) HMW-kininogen (0.2 U/ml), (C) PTA (0.2 U/ml), (D) ellagic acid (0.1 mM), or (E) BSA. The mixtures were further incubated for 10 min, and 0.05-ml aliquots were tested as above.
in comparison to HF-ellagic acid (Table II) . The addition of HF-ellagic acid shortened the PTT of Hageman trait and Fletcher trait plasmas from >400 s to 186.0 and 134.0 s, respectively. But it did not significantly shorten the PTT of Fitzgerald trait plasma, consistent with our earlier studies using HF-kaolin (12) . In contrast, the addition of HF-fragments shortened the prolonged PTT of Hageman trait and Fitzgerald trait plasmas to 198.0 and 175.5 s, respectively; HF-fragments corrected the PTT of both Hageman trait and Fitzgerald trait plasmas to the same degree. The concentration of HF-fragments required to give the same degree of correction in Hageman trait was -100 x as great as that of HF on a weight basis. The coagulant activity of HF-fragments upon Fitzgerald trait plasma was unaffected when this plasma was reconstituted with HMW-kininogen. In contrast, the effect of HF-ellagic acid upon the reconstituted plasma was dramatic (Table II , Exp B). These experiments suggest that HF-fragments can activate PTA in the absence of HMW-kininogen. This possibility was studied in a purified system. When PTA was incubated with HF-fragments, plasma prekallikrein, HMW-kininogen, and ellagic acid, and aliquots of this mixture were tested upon a substrate of PTA-deficient plasma, the clotting time progressively shortened with time (Table III) . The generation of activated PTA activity was unaffected when HMW-kininogen, plasma prekallikrein, and ellagic acid were removed from the mixture. But no activation of PTA occurred without the addition of HF-fragments. These experi-590 Exp. A: in a 10 x 75-mm polystyrene tube, 0.1 ml test plasma was incubated at 37'C for 1 min with 0.1 ml Centrolex 0, and 0.15 ml HF-fragments (18 ,ug/ml) or HF-ellagic acid mixture (HF-0.2 ,ug/ml, ellagic acid 0.03 mM). 0.1 ml 0.025 M CaCl2 was then added to the mixture and the clotting time recorded at 37°C. Exp. B: in a 10 x 75-mm polystyrene tube, a mixture of 0.8 ml test plasma and 0.2 ml HMW-kininogen (K) (5 U/ml) or barbital-saline buffer was incubated at 37'C for 1 min with 0.1 ml Centrolex 0 and 0.15 ml HF-fragments (10 ,ug/ml) or HF-ellagic acid mixture (HF 0.1 ,ug/ml, ellagic acid 0.03 mM). The tube was then recalcified and tested as above. The results were the mean of the duplicate determinations.
ments suggest that HF-fragments directly activate PTA in the absence of ellagic acid and HMWkininogen, and that HMW-kininogen does not enhance the action of HF-fragments.
Evidence that no fragmentation of HF occurs in a mixture of HF, PTA, HMW-kininogen, and ellagic acid. Since HF-fragments activated PTA without the participation of ellagic acid or HMW-kininogen, we tested the possibility that HF-fragments may be generated in a mixture of HF, PTA, HMW-kininogen, and ellagic acid. When 1251-HF was incubated with HMW-kininogen, PTA, and ellagic acid, and aliquots were subjected to SDS-gel electrophoresis after reduction with 8-mercaptoethanol, no significant radioactivity was found in the lower molecular weight region.
DISCUSSION
In 1974, we described a new asymptomatic disorder (Fitzgerald trait) of blood coagulation associated with impaired surface-mediated fibrinolysis, kinin generation, and enhancement of vascular permeability by diluted plasma (5, 6) . Subsequently, five additional unrelated individuals have been described who have the same clotting defect as Fitzgerald trait (10, 13, 14, 29 deficient in the plasma of their patient (Flaujeac trait) as high molecular weight (HMW)-kininogen. Almost simultaneously, the same finding was reported in other individuals with the same clotting defect (12) (13) (14) . Although individuals with HMW-kininogen deficiencies (11) (12) (13) (14) have the same clotting defect, they exhibited different defects in the kinin-forming system. The plasma concentrations of prekallikrein and low molecular weight kininogen were quite variable in different cases. Mr. Fitzgerald's plasma is functionally deficient in HMW-kininogen (12) , whereas plasmas of other patients (11, 13, 14) are more or less deficient in both low molecular weight and HMW-kininogen. Plasma prekallikrein activity in some patients (12) (13) (14) is low (10-45% of normal plasma), and in others (11) is normal. Therefore, each case must be studied carefully to elucidate the interactions of agents involving blood coagulation and kinin formation.
In the present study, HMW-kininogen was highly purified from normal human plasma (1,200 times purified over plasma) by monitoring its clot-promoting activity, using Fitzgerald trait plasma as a substrate. the HMW-kininogen clotting assay is an easy and quick way to localize HMW-kininogen during the fractionation of plasma compared to the time-consuming kininogen assay. Our earlier preparations of HMW-kininogen monitored by this assay released, however, only small amounts of kinin activity upon kallikrein or trypsin treatment. This was probably In a 10 x 75-mm polystyrene tube, the following prewarmed reagents were incubated at 37°C: 0.075 ml PTA (0.2 U/ml), 0.025 ml HMW-kininogen (K) (0.04 U/ml), 0.025 ml prekallikrein (0.2 U/ml), 0.075 ml HF-fragments (HFf) (27 ,ug/ml) and 0.025 ml ellagic acid (EA) (0. (30) . Removal of kinin from HMW-kininogen by action of trypsin resulted in loss of its clot-promoting activity. In contrast, HMW-kininogen retained its ability to repair the impaired clotting and fibrinolysis of Fitzgerald trait plasma when comparable amounts of kinin activity were removed by plasma kallikrein. Furthermore, HMW-kininogen, from which all kinin activities were removed, functioned equally well in the activation of PTA in a purified system. These findings are in agreement with data reported by Colman et al. (14) , but are in contrast with a recent report that treatment of HMW-kininogen with kallikrein decreases its potentiating effect in the activation of prekallikrein by activated HF (31) . Recently, Japanese researchers demonstrated that a potent inhibitor of blood coagulation (a histidine-rich peptide) was released from bovine HMW-kininogen by plasma kallikrein (32) . Although no detailed structure of human HMW-kininogen comparable to that of bovine protein has yet been reported, no such inhibitory activity was identified in the present study.
Normal human plasma clots rapidly upon contact with a foreign surface such as glass through a sequence of reactions designated as the intrinsic pathway of thrombin formation. It was originally thought that activated HF (Factor XIIa) directly activates PTA (33, 34) . Studies on Fletcher trait plasma (7) (8) (9) suggest that plasma prekallikrein may be needed for optimal activation of PTA in plasma. Schiffman and Lee (35) , however, could not activate PTA in a mixture of kaolin, HF, prekallikrein, and PTA, suggesting a requirement for an additional factor (contact activation co-factor), although certain forms of 592 H. Saito activated HF (HF-fragments) have been shown to activate PTA directly (36, 37) . Earlier, we showed that Fitzgerald factor, i.e., HMW-kininogen, participated in the early steps of the intrinsic pathway before the activation of PTA (6) . Subsequently, the identity of Fitzgerald factor and contact activation co-factor was reported (38) .
In the present study, the role of HMW-kininogen as well as HF, PTA, and plasma prekallikrein in the activation of PTA was studied in a purified system. Immunologic studies (Fig. 4 A, B) identified the clot-promoting agent generated as activated PTA. It was possible to follow the time-course of activation of PTA by using ellagic acid as an activator and appropriate dilutions of purified clotting factors. In all experiments, the reaction was triggered by adding ellagic acid to a mixture containing purified proteins to simulate the activation of PTA in whole plasma. It appeared that HMW-kininogen is absolutely necessary for the activation of PTA by HF and ellagic acid. In contrast to recent reports (39, 40), we could not show an additional effect of plasma prekallikrein. Our preparations of PTA and prekallikrein had much higher specific activity compared to those in an earlier report (40) . One possible explanation is that our HF preparations had already been modified during purification, so that they no longer needed prekallikrein for-their effect.
The role of each component in the activation of PTA was further studied by changing the concentration of each reagent. Because the system under study is complex, we could not measure the initial velocity of the reaction. Therefore, we measured the yield of activated PTA and tested the effect of further additions of each component after the reaction had reached a plateau. Kinetic studies showed that the yield of activated PTA was related to the amounts of PTA, HF, and HMW-kininogen in the mixtures. Our results are consistent with the hypothesis that neither HF, PTA, nor HMW-kininogen alone can act catalytically, but they may form a complex in the presence of ellagic acid. Whether activated PTA remains attached to a complex is not clear. As far as HMWkininogen is concerned, this is consistent with a previous report (41) that the amount of activated PTA was proportional to the amount of contact activation co-factor (HMW-kininogen) present. Griffin and Cochrane (40) (Table  II) and in a purified system (Table III) . The reconstitution of HMW-kininogen-deficient plasma with HMW-kininogen did not enhance the action of HFfragments in the clotting system. The possibility that fragmentation of HF had taken place in a mixture of HF, PTA, HMW-kininogen, and ellagic acid is unlikely. Even if it occurs, the amount of HF-fragments derived from HF in the mixture would be too little to be clot-promoting.
Thus, it appears that there were two distinct ways to activate PTA in our studies, by HF-HMWkininogen-ellagic acid or by HF-fragments. Which pathway is the major one in whole plasma remains to be determined. In this regard, it is interesting to note that 125I-HF was cleaved very slowly into 28,000 mol wt fragments in prekallikrein or HMWkininogen-deficient plasmas exposed to glass (42) . It is well known that the PTT of prekallikrein-deficient plasma, but not of HMW-deficient plasma, becomes normal after prolonged exposure to surfaces (4, 12) , activation of PTA in prekallikrein-deficient plasma may not be dependent upon the generation of HFfragments. Further work is needed to explain the data obtained in purified systems and to elucidate the mode of activation of PTA in whole blood.
